Cyclosporine A (CsA) is one of the most effective systemic drugs available for the treatment
of psoriasis, as evidenced by the results of several randomized studies and by a prolonged …

Introduction Although the introduction of biologics and targeted synthetic disease-modifying
antirheumatic drugs (tsDMARDs) has reshaped the treatment paradigm for immune …

Psoriasis is a chronic inflammatory disease that affects 1.3% of the Brazilian population. The
most common clinical manifestations are erythematous, scaling lesions that affect both …

Cyclosporine (CsA) is a calcineurin inhibitor that acts selectively on T cells. It has been used
in dermatology since 1997 for its US Food and Drug Administration indication of psoriasis …

Background: Psoriasis is a chronic, inflammatory, relapsing and remitting disease with no
cure till date. There is a paucity of trials using a combination of methotrexate (MTX) and …

Objective A prospective, randomized clinical study to compare the short-term effects of
cyclosporin and acitretin on psoriasis severity, and serum interleukin (IL)-2 and tumour …

Background: In the literature as well as in existing psoriasis guidelines, only little evidence is
available on combination regimens with systemic antipsoriatic agents. However, if systemic …

Представлен обзор рандомизированных исследований, в которых приняли участие
пациенты с тяжелым псориазом, показавших, что после 10-12 недель монотерапии …

Milano/Londra/New York 25 luglio 2017–NB Renaissance Partners (“NBRP”), l'attività di
Neuberger Berman dedicata agli investimenti di private equity in Italia, annuncia di aver …

Psoriasis is a common, chronic, disfiguring, inflammatory, and proliferative condition of the
skin. It manifests with varying degrees of severity and can be treated with various immune …